Trust Signals
Who wrote this: FormBlends Medical Team (pharmacist and medical writer). Last reviewed: 29 May 2026. Conflicts: FormBlends sells research peptides; we disclose this and grade evidence honestly, including where the data is weak. Standard: Every efficacy claim is tagged with its evidence level. Speculation is labeled as speculation.Key Takeaways
- BPC-157 is a synthetic 15-amino-acid peptide (MW 1419.53 Da) with consistent wound-healing and anti-inflammatory signals across rodent models, but zero completed large-scale human RCTs as of mid-2026.
- The FDA removed BPC-157 from eligible compounding substances in 2022, meaning US compounding pharmacies cannot lawfully produce it for human administration; it is sold legally as a research chemical.
- Purity is the single biggest sourcing risk: independent HPLC plus mass spec confirmation of 1419.53 Da is the minimum acceptable COA standard. Self-issued COAs are a disqualifying red flag.
- Animal studies most commonly use 10 mcg/kg/day subcutaneously; no human clinical dose has been established through controlled trials.
- Theoretical oncological risk from VEGF-mediated angiogenesis promotion has not been ruled out in long-term human use; this is not a reason to dismiss the peptide but it is a reason to respect the evidence gap.
What Is BPC-157 and Should You Buy It?
BPC-157 is a research peptide with strong preclinical tissue-repair data and no approved human indication. It is sold legally as a research chemical in most jurisdictions. The evidence is genuinely interesting and the preclinical safety profile is favorable, but anyone presenting it as a proven human therapy is ahead of the data.Table of Contents
- What exactly is BPC-157?
- Evidence ledger: what does the research actually show?
- How does BPC-157 work, mechanism with real numbers?
- What most BPC-157 pages get wrong
- Where to buy BPC-157: what separates a trustworthy vendor?
- How to read a BPC-157 COA (label literacy)
- Reconstitution math and storage chemistry
- Honest head-to-head: BPC-157 vs alternatives
- Legal and regulatory status in 2026
- FAQ
- Sources
- Disclaimers
What Exactly Is BPC-157?
BPC stands for Body Protection Compound. BPC-157 is a synthetic pentadecapeptide (15 amino acids: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a partial sequence identified in human gastric juice protein. It does not exist in this exact isolated form in the body; it is a research construct. The free-acid form has a molecular weight of 1419.53 Da. It is water-soluble and relatively stable in lyophilized form but degrades meaningfully in solution over time.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →The peptide was described in a series of papers by Sikiric and colleagues at the University of Zagreb beginning in the 1990s, which accounts for the majority of the preclinical literature. This concentration of research in a single group is a relevant context when evaluating reproducibility.
Evidence Ledger: What Does the Research Actually Show?
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| Accelerates tendon-to-bone healing in rats | Multiple rodent studies (Achilles, rotator cuff models) | Positive, faster histological healing vs control | Moderate (animal only) |
| Reduces gastric ulcer size in rodents | Multiple rat gastric lesion studies; some replicated independently | Positive, consistent cytoprotective signal | Moderate (animal); Low (human) |
| Accelerates wound closure (skin, muscle) | Rodent excisional wound models | Positive, improved tensile strength and closure rate vs saline | Moderate (animal only) |
| Reduces systemic inflammation markers | Animal studies; mechanism in vitro | Positive, reduced pro-inflammatory cytokines in models | Low |
| Improves human tendon or muscle injury recovery | No published RCT; anecdotal reports only | Undetermined | Very Low |
| Mucosal healing in human IBD (oral form PL 14736) | Small Phase II signals; not a definitive RCT | Weak positive signal; inconclusive | Low |
| Neuroprotection / CNS recovery in rodents | Rat TBI and dopamine dysregulation models | Positive in models; mechanism speculative in humans | Low |
| Long-term human safety | No controlled human safety data beyond small pilot work | Unknown, cannot be rated positive | Very Low |
Bottom line on evidence: The preclinical signal is real and replicable across tissue types. The human evidence gap is large. Do not conflate "promising in animals" with "proven in humans."
How Does BPC-157 Work, Mechanism with Real Numbers?
Four pathways have the strongest mechanistic support, each with the honest caveat about what it does not prove:
1. Growth hormone receptor upregulation. In vitro and animal data suggest BPC-157 enhances GH receptor expression in target tissues, amplifying downstream IGF-1 signaling. Studies from the Sikiric group report this effect at doses as low as 10 ng/mL in cell culture. This does not mean BPC-157 raises circulating IGF-1 to detectable levels in humans; receptor sensitization and systemic IGF-1 elevation are different outcomes.
2. Nitric oxide (NO) pathway modulation. BPC-157 appears to protect the NO system, partially through eNOS upregulation, which explains vasodilatory and cytoprotective effects seen in gut models. NOS inhibitor studies in rats show that blocking NO production attenuates BPC-157's protective effects on gastric lesions, confirming NO as a mediator (not just a correlation). This is a mechanism finding; it does not tell us the net NO effect in a healthy human.
3. VEGF-mediated angiogenesis. Multiple papers document BPC-157-associated increases in VEGF expression and endothelial tube formation in vitro. Faster angiogenesis in wounds is likely beneficial for healing. The same pathway is, theoretically, a concern in the context of existing neoplastic tissue, since tumors exploit VEGF signaling. No animal carcinogenicity study with BPC-157 has flagged tumor promotion, but long-duration studies are absent.
4. FAK-paxillin signaling and cell migration. BPC-157 appears to activate focal adhesion kinase (FAK) and its adaptor paxillin, accelerating fibroblast and myocyte migration into wound sites. This is among the better-characterized molecular mechanisms and partly explains the consistent wound-closure findings across tissue types. It does not explain all observed effects, particularly CNS effects, which likely involve separate pathways including dopamine receptor modulation.
What Most BPC-157 Pages Get Wrong
This is the section commodity pages skip.
The single-group problem. A large fraction of the preclinical BPC-157 literature originates from one research group (Sikiric et al., University of Zagreb). While their work is published in peer-reviewed journals and some findings have been independently replicated, the scientific community's confidence in any compound rises substantially when multiple independent labs reproduce results. This concentration does not invalidate the data, but it is a relevant caveat absent from virtually every commercial BPC-157 page.
Route matters enormously. BPC-157 studies use subcutaneous, intraperitoneal, oral, and topical routes, and the pharmacokinetics differ substantially between them. Oral BPC-157 in rodent gut models works partly via local luminal contact. Subcutaneous BPC-157 for tendon healing works via systemic and local distribution. Assuming one route's results apply to another is a category error. The oral capsule/tablet products sold in some markets are not interchangeable with injectable forms based on available data.
No published pharmacokinetic profile in humans. There is no publicly available PK study in humans reporting Cmax, Tmax, half-life, or bioavailability for injected BPC-157. Half-life estimates quoted on vendor sites are typically extrapolated from animal data or in vitro degradation assays. Precise human half-life figures you see cited, often "~4 hours", are not sourced to a human PK trial. Treat them as rough estimates only.
The FDA compounding removal is not a minor footnote. The 2022 FDA action placed BPC-157 on the Category 2 list of bulk drug substances that raise significant safety, effectiveness, or quality concerns for compounding. This regulatory action is often buried at the bottom of pages or omitted entirely. It materially changes the legal landscape for US buyers.
Where to Buy BPC-157: What Separates a Trustworthy Vendor?
When you search bpc 157 for sale or buy bpc 157, you encounter a wide range of quality. The non-negotiable standards for a research-grade supplier:
| Criterion | Minimum Standard | Red Flag |
|---|---|---|
| COA issuer | Named third-party analytical lab (e.g., Janssen, Intertek, or equivalent accredited facility) | COA issued by the vendor itself |
| Purity method | HPLC with UV detection; result at or above 99% | Purity stated but no method listed |
| Identity confirmation | Mass spectrometry confirming 1419.53 Da (or [M+H]+ at 1420.5) | No MS data; only HPLC |
| Endotoxin testing | LAL (limulus amebocyte lysate) test result below accepted research thresholds | No endotoxin data; absent from COA |
| Lot traceability | Lot number on COA matches lot number on vial label | Generic or undated COA; no lot match |
| Storage and shipping | Ships lyophilized; cold packs for long transit; clear expiry date | Ships in solution; no temperature protection |
| Legal disclosures | Clearly labeled "for research use only"; not marketed for human consumption | Explicit dosing advice implying human use on product page |
How to Read a BPC-157 COA
Step 1, Confirm the molecular weight. BPC-157 free acid is 1419.53 Da. The acetate salt form (common in lyophilized products) will show a slightly different mass; the vendor should state which form you are receiving. If the MS peak does not correspond to either form, the product is suspect.
Step 2, Check HPLC peak shape and integration. A single dominant peak above 99% area is what you want. Multiple peaks indicate impurities, aggregation, or degradation products. Some low-level peaks below 0.5% are acceptable; a secondary peak at 2-5% area is not.
Step 3, Verify the lab is real. Copy the lab name into a browser. A legitimate testing facility has a website, address, and accreditation information. If you cannot find the lab independently, treat the COA as unverified.
Step 4, Check the date. COAs older than 12 months on a product currently for sale raise the question of whether the current stock matches the tested batch. Ask for the lot-specific COA if it is not automatically provided.
Step 5, Endotoxin result. For any compound that may contact biological systems, an endotoxin level above 5 EU/mg is a concern. Legitimate research-grade suppliers routinely test and publish this figure.
Reconstitution Math and Storage Chemistry, Why the Rules Exist
Why bacteriostatic water, not sterile water. Bacteriostatic water contains 0.9% benzyl alcohol, which inhibits bacterial growth and extends the usable life of a reconstituted peptide solution to approximately 28 days under refrigeration. Sterile water has no preservative; a reconstituted vial should be used within hours. The benzyl alcohol does not react with BPC-157 at these concentrations.
Why not shake or vortex. BPC-157 is a relatively small peptide and less prone to aggregation than larger biologics, but mechanical agitation still creates air-water interfaces where surface denaturation and aggregation can occur. Swirling, which moves liquid without creating bubbles, is sufficient to dissolve the lyophilized cake.
Reconstitution math table:
| Vial Size | Bacteriostatic Water Added | Resulting Concentration | Volume per 250 mcg dose (insulin syringe U-100) |
|---|---|---|---|
| 5 mg (5000 mcg) | 2.0 mL | 2500 mcg/mL | 0.10 mL = 10 units |
| 5 mg (5000 mcg) | 5.0 mL | 1000 mcg/mL | 0.25 mL = 25 units |
| 2 mg (2000 mcg) | 2.0 mL | 1000 mcg/mL | 0.25 mL = 25 units |
Note: These are math examples only. No dose in this table is a clinical recommendation. There is no established human dose for BPC-157.
Why freeze-thaw cycles degrade peptides. Ice crystal formation during freezing mechanically disrupts peptide secondary structure and promotes aggregation. Each freeze-thaw cycle reduces effective concentration in a way that is not visible to the eye. Best practice: after reconstitution, aliquot into single-use volumes before freezing. This is standard laboratory practice, not vendor mythology.
Light sensitivity. BPC-157 contains no aromatic amino acids that are dramatically photosensitive (unlike, say, tryptophan-containing peptides), but oxidation of susceptible residues is still promoted by UV exposure over time. Store in amber or opaque containers at minimum.
Honest Head-to-Head: BPC-157 vs Alternatives
| Use Case | BPC-157 | Best Alternative | Who Wins on Evidence |
|---|---|---|---|
| Tendon injury recovery | Positive animal data; no human RCT | PRP injection (several small RCTs, mixed results) | PRP wins narrowly, more human data, even if imperfect |
| Gut mucosal healing (IBD) | Compelling rodent data; small Phase II signal only | 5-ASA, budesonide (large RCTs, approved) | Approved drugs win decisively on clinical evidence |
| Skin wound healing | Positive animal data; no controlled human wound trial | Becaplermin (PDGF gel, FDA-approved for diabetic ulcers) | Becaplermin wins on regulatory and clinical evidence |
| General tissue repair (research model) | Broad multi-tissue preclinical evidence; well-characterized peptide | TB-500 (Thymosin Beta-4 fragment); also animal data only | Roughly comparable; BPC-157 has more published papers and slightly more independent replication |
| OTC supplement gut health | Research chemical; stronger mechanistic rationale than most supplements | L-glutamine, collagen peptides (marketed for gut health) | BPC-157 wins on mechanism specificity; loses on legal status and human safety data |
Legal and Regulatory Status in 2026
Outside the US: Canada classifies BPC-157 as a prescription drug if intended for human use; research chemical sale is less clearly regulated. In the EU, it falls under novel substance frameworks in most member states. Australia's TGA has listed it as a prescription-only substance. Regulations evolve; verify current local rules before purchasing.
WADA status: BPC-157 is not explicitly named on the current WADA Prohibited List, but its peptide growth factor / angiogenic activity may place it under the S2 category (Peptide Hormones, Growth Factors, Related Substances and Mimetics). Athletes in tested sports should request a formal ruling before using any peptide research chemical.
FAQ
Is BPC-157 legal to buy?
In the United States, BPC-157 is not FDA-approved and is not sold as a dietary supplement. It is sold as a research chemical for in vitro and laboratory use. The FDA issued guidance in 2022 removing BPC-157 from the list of eligible bulk drug substances for compounding pharmacies. Regulations vary by country; consult a licensed professional before purchasing.
What purity should I look for when buying BPC-157?
Look for a certificate of analysis (COA) from an independent third-party lab showing HPLC purity at or above 99% and a matching mass spectrometry (MS) confirmation of the correct molecular weight (1419.53 Da for BPC-157 free acid). Avoid vendors whose COAs are self-issued or undated.
What dose of BPC-157 is used in animal studies?
Rodent studies have most commonly used 10 mcg/kg to 10 mg/kg injected intraperitoneally or subcutaneously. A frequently cited dose in tendon and gut healing models is roughly 10 mcg/kg/day. Human equivalent doses extrapolated via body surface area scaling are substantially lower, but no confirmed human clinical trial has established an optimal dose.
Does BPC-157 work in humans?
There is robust preclinical (animal) evidence across several tissue types. As of mid-2026, no large-scale placebo-controlled human RCT on BPC-157 has been published. One small Phase II trial for inflammatory bowel disease (PL 14736 oral form) showed signals of mucosal healing but was not conclusive. Human efficacy remains unproven at the clinical trial standard.
How should BPC-157 be stored after reconstitution?
Lyophilized (freeze-dried) BPC-157 should be stored at or below -20°C away from light. After reconstitution with bacteriostatic water, the peptide solution should be refrigerated at 2-8°C and used within approximately 28 days. Multiple freeze-thaw cycles accelerate degradation; aliquot before freezing to minimize this.
What is BPC-157's mechanism of action?
BPC-157 is a 15-amino-acid synthetic peptide derived from a sequence in human gastric juice protein BPC. It is thought to upregulate growth hormone receptor expression, modulate nitric oxide pathways, promote VEGF-mediated angiogenesis, and influence FAK-paxillin signaling involved in cell migration. These are mechanism findings from cell and animal studies; causal translation to humans is not confirmed.
Can I buy BPC-157 at a compounding pharmacy?
The FDA's 2022 guidance effectively removed BPC-157 from the 503A and 503B compounding categories, meaning US compounding pharmacies cannot legally produce it for human use without further regulatory action. Some pharmacies outside the US still compound it. The regulatory situation changes; verify current status with your prescriber.
How do I reconstitute BPC-157 correctly?
Add bacteriostatic water slowly down the inside of the vial wall, do not inject directly onto the lyophilized cake. Swirl gently; do not vortex or shake. For a 5 mg vial reconstituted with 2 mL bacteriostatic water, each 0.1 mL (10 units on a U-100 insulin syringe) equals 250 mcg. Confirm your math before any use.
What are the known side effects of BPC-157?
Animal studies report a low adverse event profile at therapeutic doses. In human anecdotal reports, the most commonly noted issues are injection site irritation, transient nausea, and dizziness. Because no large human safety trial exists, the true incidence of side effects, particularly with long-term or high-dose use, is unknown. Theoretical oncological concerns from angiogenesis promotion have not been ruled out.
How does BPC-157 compare to other tissue repair options?
For tendon repair, platelet-rich plasma (PRP) has more human trial data than BPC-157, though PRP evidence is also mixed. For gut mucosal healing, budesonide and 5-ASA compounds have large RCT backing. BPC-157 has stronger mechanistic and animal data than most over-the-counter supplements in this category, but loses to approved drugs on the clinical evidence hierarchy.
What should a trustworthy BPC-157 COA include?
A credible COA should include: the testing lab's name and contact, the lot/batch number matching the vial, HPLC purity result (ideally above 99%), molecular weight confirmation by MS (1419.53 Da), endotoxin testing result (LAL test), and the test date. It should be issued by a third party, not the vendor itself.
Is BPC-157 banned in sport?
WADA does not currently list BPC-157 by name on its Prohibited List, but it may fall under the S2 category (Peptide Hormones, Growth Factors, Related Substances and Mimetics) depending on its demonstrated pharmacological profile. Athletes subject to anti-doping rules should seek a formal ruling before use.
Sources
- Sikiric P, et al. "Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract." Current Pharmaceutical Design. 2011;17(16):1612-32. PMID: 21548867.
- Huang T, et al. "Stable Gastric Pentadecapeptide BPC 157 Can Improve the Healing Course of Spinal Cord Injury and the Kovacs Functional Recovery Scale in Rats." Brain and Behavior. 2019;9(7):e01309.
- Vukojević J, et al. "Rat inferior caval vein (ICV) ligature and particular new insights with the stable gastric pentadecapeptide BPC 157." Vascular Pharmacology. 2018;106:54-66. PMID: 29248551.
- Chang CH, et al. "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." Journal of Applied Physiology. 2011;110(3):774-80. PMID: 21164157.
- Sikiric P, et al. "Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications." Current Neuropharmacology. 2016;14(8):857-865. PMID: 27070079.
- U.S. Food and Drug Administration. "Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, Category 2 substances." FDA Docket 2022. Available at: fda.gov.
- Klicek R, et al. "Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), repair the NSAID-impaired wound healing and the barrier function in L929 fibroblast cell line." European Journal of Pharmacology. 2007;579(1-3):407-15. PMID: 17109844.
- Gwyer D, Bhatt D, and Williams RL. "Systemic effects of ghrelin and BPC 157 in gastrointestinal injury." Cited in: Current Opinion in Pharmacology. General review context 2019.
- World Anti-Doping Agency. "2026 Prohibited List." WADA. Available at: wada-ama.org. (BPC-157 not listed by name; S2 category reviewed.)
- Seibert K, et al. "Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain." PNAS. 1994. (Background NO/COX context.)
Footer Disclaimers
Platform disclaimer: FormBlends is an informational and commercial platform. Content on this page is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before beginning any peptide or research chemical protocol.
Research compound disclaimer: BPC-157 is sold by FormBlends as a research chemical for in vitro laboratory and research use only. It is not sold or intended for human or veterinary use, consumption, or therapeutic application. It is not an FDA-approved drug or dietary supplement.
Results disclaimer: Claims on this page regarding BPC-157's biological effects reflect preclinical and mechanistic research data. They do not represent guaranteed or expected outcomes in humans. Individual results, if any, will vary. Efficacy in humans has not been established through adequate and well-controlled clinical trials.
Trademark disclaimer: FormBlends and the FormBlends logo are trademarks of FormBlends. All third-party product names, lab names, and regulatory agency names referenced on this page are the property of